About Editas Medicine
Editas Medicine is a publicly listed company based in Cambridge (United States) founded in 2013 by George M Church. Therapeutics for rare genetic diseases are developed using CRISPR technology. Editas Medicine has raised $210 million across 5 funding rounds from investors including Fidelity Investments, Juno Therapeutics and Dr. Reddy's Laboratories. The company has 246 employees. Its chief executive, as recorded, is Cynthia Collins. Its website editasmedicine.com draws about 11 thousand monthly visits. Editas Medicine offers products and services including CRISPR Gene Editing Technology and Experimental Medicines Pipeline. Its focus areas include Life Sciences, Gene Therapy, DNA and CRISPR. Its competitors include Insitro, BridgeBio and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics for rare genetic diseases. It has developed a novel class of genome editing therapeutics using CRISPRCas genome editing technology. It is utilized for the treatment of rare genetic eye diseases including Leber congenital amaurosis, and usher syndrome. It is also used for the treatment of beta-thalassemia, Duchenne muscular dystrophy, sickle cell anemia, cystic fibrosis, alpha 1-antitrypsin deficiency, and many more.
- Headquarters Cambridge, United States
- Employees 246
- Founders George M Church
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website editasmedicine.com
- Social LinkedIn X
- Legal Name Editas Medicine, Inc.
- Annual Revenue$40.52 M (USD)25.39as on Dec 31, 2025
- Net Profit-$160.06 M (USD)32.49as on Dec 31, 2025
- EBITDA-$94.06 M (USD)59.65as on Dec 31, 2025
- Total Equity Funding$210M (USD)
in 5 rounds
- Latest Funding Round$2M (USD), Post-IPO
Dec 2023
- InvestorsFidelity Investments
& 17 more
- Employee Count246
Products & Services of Editas Medicine
Editas Medicine offers a comprehensive portfolio of products and services, including CRISPR Gene Editing Technology and Experimental Medicines Pipeline.
Technology for revising, removing, and replacing DNA to treat serious diseases.
Pipeline of medicines aimed at developing durable therapies for patients.
Funding Insights of Editas Medicine
Editas Medicine has successfully raised a total of $210M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $210M
- Total Rounds 5
- Last Round Post-IPO — $2M
- First Round $43M
(Nov 2013)
- Investors Count 18
All 5 funding rounds of Editas Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $2M | Post-IPO | – | – | |
| Aug 2015 | $120M | Series B | – | Boris Nikoli | |
| Jul 2015 | $220,430 | Grant | – | – | |
| May 2015 | $47M | Private Equity Round | – | – | |
| Nov 2013 | $43M | Series A | – | – |
18 investors in total: 17 institutional and 1 angel.
Investors in Editas Medicine
Editas Medicine has secured backing from 18 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Fidelity Investments, Juno Therapeutics and Dr. Reddy's Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Venture capital firm | omegafunds.com | Boston, United States | ||
Innovative medicines are developed and manufactured globally by the company. | 1984 | drreddys.com | Hyderabad, India |
Investor details for Editas Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Editas Medicine
87 people are tracked at Editas Medicine (47 in leadership, 4 in board & advisors, 36 in team); the tracked headcount is 246.
| Name | Role | Group |
|---|---|---|
George M Church | Co-Founder | Leadership |
Cynthia Collins | Ex-CEO & President | Leadership |
Salvatore Iovino | Senior Director, Bioanalytical And Biomarker Sciences | Leadership |
Eugenio Marco Rubio | Director, Computational Biology | Leadership |
Stephen Pietrasiewicz | Director, Process And Delivery Chemistry | Leadership |
Carly Pirro | People Operations Partner | Leadership |
David Allen | Director, DSPV Operations/scientist | Leadership |
John Zuris | Senior Director | Leadership |
Preethi Bapna | Vp, Corporate Strategy & Communications | Chief Of Staff To CEO | Leadership |
Michael Dinsmore | Vice President, Platform Technology Group | Leadership |
Victoria Lattanzi | Associate Director | Leadership |
Brieana Cox Buckley | Senior Vice President, Development And Program Leadership | Leadership |
Aravind Ganta | Senior Director Facilities & Engineering | Leadership |
Qifeng Yu | Vice President, Head Of Biometrics | Leadership |
Judith Newmark | Associate Director, In Vivo Gene Editing-pharmacology & Toxicology | Leadership |
Harry A. | Director, Cellular Process Development | Leadership |
Linda C. Burkly | EVP & Chief Scientific Officer | Leadership |
George Church | Co-founder | Leadership |
Tom Love | Vice President, People | Leadership |
Gulum Kosova | Associate Director, Statistical Genetics | Leadership |
67 more people are available in the full profile.
Complete people profiles for Editas Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Editas Medicine
Editas Medicine is a publicly listed company on the NASDAQ with ticker symbol EDIT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Feb 2016
- Listed onFRA: 8EM
- Listed entityEditas Medicine, Inc.
- Exchange sectorHealth technology
- ISINUS28106W1036
- Share price$2.44 (-11.09% on the day) · 2026-10-13
- Market capitalisation$375.5M
- EPS (diluted, trailing year)$-0.74
- Volume (last session)2,453,760
Financials of Editas Medicine
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $40.5M | -$160.1M | -$94.1M |
| 2024 | $32.3M | -$237.1M | -$233.1M |
| 2023 | $78.1M | -$153.2M | -$163.1M |
| 2022 | $19.7M | -$220.4M | -$219.6M |
| 2021 | $25.5M | -$192.5M | -$188.1M |
Detailed financial statements for Editas Medicine
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Editas Medicine
4 dated milestones of Editas Medicine across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Editas Medicine is founded.
- Funding First funding round of $43.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $2.0M.
Competitors of Editas Medicine
Editas Medicine has 3 listed competitors in our database, 3 of them funded. They include Insitro, BridgeBio and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Editas Medicine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Editas Medicine
The website of Editas Medicine (editasmedicine.com) receives about 11K visits a month.
- Monthly visits11K
▲ 0.9% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Editas Medicine (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Editas Medicine
Complete news archive for Editas Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Editas Medicine
Editas Medicine was founded in 2013.
Editas Medicine is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Cynthia Collins is the CEO of Editas Medicine, as recorded in our data.
Editas Medicine is a funded company, having raised a total of $210M across 5 funding rounds to date. The company's 1st funding round was a Series A of $43M, raised on Nov 2013.
Editas Medicine has 246 employees.
Annual revenue of Editas Medicine is $40.52M as on Dec 31, 2025.
Developer of therapeutics for rare genetic diseases. It has developed a novel class of genome editing therapeutics using CRISPRCas genome editing technology. It is utilized for the treatment of rare genetic eye diseases including Leber congenital amaurosis, and usher syndrome. It is also used for the treatment of beta-thalassemia, Duchenne muscular dystrophy, sickle cell anemia, cystic fibrosis, alpha 1-antitrypsin deficiency, and many more.
Editas Medicine offers CRISPR Gene Editing Technology and Experimental Medicines Pipeline.
Yes, Editas Medicine is publicly traded on NASDAQ under the ticker symbol EDIT.
Editas Medicine has 18 investors. Key investors include Fidelity Investments, Juno Therapeutics, Dr. Reddy's Laboratories, Khosla Ventures, and T. Rowe Price.